文献速递泌尿系感染男科与性医学

阴道雌激素有效预防绝经后女性复发性尿路感染:泌尿科诊疗绝经泌尿生殖综合征的要点

Effective Prevention of Recurrent UTIs With Vaginal Estrogen: Pearls for a Urological Approach to Genitourinary Syndrome of Menopause.
PubMed 文献 · Urology · 2020-06-10

本文综述阴道雌激素制剂预防绝经后女性复发性尿路感染(rUTI)的证据,并为泌尿科医生识别和治疗绝经泌尿生殖综合征(GSM)提供框架。

要点

  • 局部阴道雌激素被多项随机临床试验证实可有效治疗绝经后女性rUTI。
  • GSM诊断以临床为主,可辅以阴道pH>5、阴道成熟指数改变等客观指标。
  • 2019年AUA/CUA/SUFU指南支持局部阴道雌激素用于rUTI。

核心结论

  • 多项随机临床试验已证实局部雌激素制剂治疗绝经后女性复发性尿路感染有效。

研究设计与样本

  • 本文为综述,检索MEDLINE和Cochrane Central Register of Controlled Trials数据库。

主要发现

  • 在未治疗GSM的情况下,rUTI(12个月内至少3次或6个月内至少2次UTI发作)的病因尚未完全阐明,但雌激素缺乏是促进因素。
  • GSM诊断主要为临床诊断,支持性客观发现包括阴道pH>5、阴道成熟指数中表层细胞减少和/或旁基底层细胞比例增加。

关键数值与推荐

  • rUTI定义为12个月内至少3次UTI发作或6个月内至少2次发作。
  • GSM支持性客观指标包括阴道pH>5、表层细胞减少和/或旁基底层细胞比例增加。
  • 常用GSM治疗包括局部阴道雌激素、脱氢表雄酮(普拉睾酮)和奥培米芬。

临床怎么用

  • 本文为评估GSM、开具局部阴道激素制剂提供框架,并汇总支持2019年AUA/CUA/SUFU指南推荐局部阴道雌激素用于rUTI的证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To review the available data related to the prevention of recurrent urinary tract infection (rUTI) in postmenopausal women with vaginal estrogen preparations and provide the urologic community with the confidence to identify and treat genitourinary syndrome of menopause (GSM). MATERIALS AND METHODS: A literature search of MEDLINE and the Cochrane Central Register of Controlled Trials databases was performed to identify studies utilizing vaginal estrogen in the treatment of urological conditions related to rUTI and GSM. RESULTS: In the setting of untreated GSM, the etiology of rUTIs (at least 3 episodes of UTIs in 12 months or at least 2 episodes in 6 months) is not fully elucidated, but estrogen deficiency is a contributing factor. The diagnosis of GSM is primarily a clinical diagnosis supported by other objective findings including: a vaginal pH >5, decreased content of superficial cells, and/or increased proportion of parabasal cells on vaginal maturation index. Local vaginal estrogen, dehydroepiandrosterone (prasterone), and ospemifene are commonly used GSM treatments. Thirty-one trials were identified utilizing estrogen preparations for rUTI in postmenopausal women. CONCLUSION: Overall, multiple randomized clinical trials have successfully been completed to show the efficacy of local estrogen preparations for the treatment of rUTIs. This high yield review provides a framework for assessing GSM, prescribing recommendations for local vaginal hormone preparations, and a summary of the substantial evidence supporting the new 2019 American Urological Association/Canadian Urological Association/Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction Guidance for local vaginal estrogen use for rUTI.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Buck ES, Lukas VA, Rubin RS, et al. Effective Prevention of Recurrent UTIs With Vaginal Estrogen: Pearls for a Urological Approach to Genitourinary Syndrome of Menopause. Urology. 2020. PMID: 32533967. doi:10.1016/j.urology.2020.05.058

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。